Palatin Technologies (PTN) EBITDA Margin (2010 - 2026)
Palatin Technologies' (PTN) quarterly EBITDA Margin came in at 40.32% in Q1 2026, up 99.36% quarter-over-quarter from 6315.75% in Q4 2025.
Analysis
Palatin Technologies (PTN) EBITDA Margin (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported EBITDA Margin for 14 consecutive years, with 40.32% the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin changed N/A year-over-year to 40.32%; the trailing twelve-month figure through Mar 2026 stood at 50.67% (up 667255.0% YoY), and the FY2024 full-year result was 501.02%, up 16773.0% from the prior year.
- EBITDA Margin grew to 40.32% in Q1 2026 per PTN's latest filing, from 6315.75% in the prior quarter.
- Across five years, EBITDA Margin topped out at 57.67% in Q4 2023 and bottomed at 6315.75% in Q4 2025.
- Historically, EBITDA Margin has averaged 1417.77% across 5 years, with a median of 612.31% in 2023.
- The widest YoY moves for EBITDA Margin: up 369025 bps in 2022, down 1872099 bps in 2022.
- Over 5 years, EBITDA Margin stood at 544.31% in 2022, then soared by 111 bps to 57.67% in 2023, then tumbled by 4233 bps to 2383.45% in 2024, then tumbled by 165 bps to 6315.75% in 2025, then jumped by 99 bps to 40.32% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 40.32%, 6315.75%, and 52.79% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | -23.56% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -25,380.93% |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | -40.32% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -40.32% |
| Dec 31, 2025 | -6,315.75% |
| Sep 30, 2025 | 52.79% |
| Jun 30, 2024 | -2,383.45% |
| Dec 31, 2023 | 57.67% |
| Sep 30, 2023 | -290.07% |
| Jun 30, 2023 | -613.99% |
| Mar 31, 2023 | -610.64% |
| Dec 31, 2022 | -544.31% |
| Sep 30, 2022 | -1,006.45% |
| Jun 30, 2022 | -1,699.81% |
| Mar 31, 2022 | -3,618.94% |
| Dec 31, 2021 | -2,623.45% |
| Sep 30, 2021 | -4,524.50% |
| Jun 30, 2021 | 17,021.18% |
| Mar 31, 2021 | -7,309.19% |
| Dec 31, 2020 | -5,641.06% |
| Sep 30, 2020 | -1,367.28% |
| Dec 31, 2019 | -27,370.73% |
| Sep 30, 2019 | -4,993.43% |